Fleishaker, Dona L <br/><br/>
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.  [electronic resource] 

 -  Arthritis research & therapy  Jan 2012 
 - R11 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-6362 
<br/><br/><label>Standard No.: </label>10.1186/ar3685  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antirheumatic Agents--adverse effects<br/>Area Under Curve<br/>Arthritis, Rheumatoid--drug therapy<br/>CCR5 Receptor Antagonists<br/>Constipation--chemically induced<br/>Cyclohexanes--adverse effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Male<br/>Maraviroc<br/>Metabolic Clearance Rate<br/>Methotrexate--adverse effects<br/>Middle Aged<br/>Nausea--chemically induced<br/>Treatment Failure<br/>Triazoles--adverse effects<br/>Young Adult